comment,amr
"Many large pharmaceutical companies abandoned the technology,[24] while some biotechs re-focused on the less profitable area of vaccines, where the doses would be at lower levels and side-effects reduced.""","# ::snt Many large pharmaceutical companies abandoned the technology,[24] while some biotechs re-focused on the less profitable area of vaccines, where the doses would be at lower levels and side-effects reduced.""
(c / contrast-01
      :ARG1 (a / abandon-01
            :ARG0 (c2 / company
                  :mod (l / large)
                  :mod (p / pharmaceutical)
                  :quant (m / many))
            :ARG1 (t / technology))
      :ARG2 (f / focus-01
            :ARG0 (c3 / company
                  :mod (b / biotech)
                  :quant (s / some))
            :ARG2 (a2 / area
                  :mod (v / vaccine)
                  :location-of (a3 / and
                        :op1 (l2 / level
                              :ARG1-of (l3 / low-04
                                    :ARG2-of (h / have-degree-91
                                          :ARG1 l2
                                          :ARG3 (m2 / more))))
                        :op2 (r / reduce-01
                              :ARG1 (e / effect-03
                                    :mod (s2 / side))))
                  :ARG1-of (h2 / have-degree-91
                        :ARG2 (p2 / profitable-02
                              :ARG1 a2)
                        :ARG3 (l4 / less)))
            :mod (a4 / again))
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication
                  :ARG0-of (c4 / cite-01
                        :ARG2 24))))"
"with most finding that the side-effects of mRNA insertion were too serious.[24][25] mRNA vaccines for human use have been developed and tested for the diseases rabies, Zika, cytomegalovirus, and influenza, although these mRNA vaccines have not been licensed.[26]","# ::snt with most finding that the side-effects of mRNA insertion were too serious.[24][25] mRNA vaccines for human use have been developed and tested for the diseases rabies, Zika, cytomegalovirus, and influenza, although these mRNA vaccines have not been licensed.[26]
(m / multi-sentence
      :snt1 (f / find-01
            :ARG1 (s / serious-02
                  :ARG1 (e / effect-03
                        :ARG0 (ii / insert-01
                              :ARG1 (m2 / mRNA))
                        :mod (s2 / side))
                  :ARG2-of (h / have-degree-91
                        :ARG1 e
                        :ARG3 (t / too)))
            :mod (m3 / most))
      :snt2 (a / and
            :op1 (d / develop-02
                  :ARG1 (v / vaccine
                        :mod (m4 / mRNA))
                  :purpose (u / use-01
                        :ARG0 (h2 / human)
                        :ARG1 v))
            :op2 (t2 / test-01
                  :ARG1 v
                  :ARG2 (d2 / disease
                        :name (n / name
                              :op1 "" rabies""))
                  :op3 (d3 / disease
                        :name (n2 / name
                              :op1 ""Z Zika""))
                  :op4 (d4 / disease
                        :name (n3 / name
                              :op1 "" cytomegalovirus""))
                  :op5 (d5 / disease
                        :name (n4 / name
                              :op1 ""influenza""))))
      :concession (l / license-01
            :polarity -
            :ARG1 (v2 / vaccine
                  :mod (t3 / this)
                  :mod (m5 / mRNA)))
      :concession (a2 / and
            :op1 d
            :op2 t2)
      :snt3 (a3 / and
            :op1 (p / publication
                  :name (n5 / name
                        :op1 ""24""))
            :op2 p
            :name (n6 / name
                  :op1 ""25"")))"
"""Up until , these mRNA biotech companies had poor results testing mRNA drugs for cardiovascular, metabolic and renal diseases; selected targets for cancer; and rare diseases like CriglerNajjar syndrome,","# ::snt ""Up until , these mRNA biotech companies had poor results testing mRNA drugs for cardiovascular, metabolic and renal diseases; selected targets for cancer; and rare diseases like CriglerNajjar syndrome,
(h / have-03
      :ARG0 (c / company
            :mod (b / biotech)
            :mod (t / this))
      :ARG1 (t2 / thing
            :ARG2-of (r / result-01)
            :mod (p / poor)
            :ARG0-of (t3 / test-01
                  :ARG1 (d / drug
                        :mod (p2 / protein
                              :name (n / name
                                    :op1 "" mRNA"")))
                  :ARG2 (a / and
                        :op1 (d2 / disease
                              :mod (h2 / heart))
                        :op2 (d3 / disease
                              :mod (m / metabolic))
                        :op3 (d4 / disease
                              :mod (r2 / renal)))))
      :time (u / until
            :op1 (n2 / now))
      :purpose (a2 / and
            :op1 (t4 / target-01
                  :ARG1 (c2 / cancer))
            :op2 (d5 / disease
                  :ARG1-of (r3 / rare-02)
                  :example (d6 / disease
                        :name (n3 / name
                              :op1 ""CriglerNajjar""
                              :op2 ""S Syndrome"")))))"
